Actuate Therapeutics (ACTU) vs Pasithea Therapeutics (KTTA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Pasithea Therapeutics (KTTA) has outperformed Actuate Therapeutics (ACTU) over the past year, losing 40.8% versus a loss of 92.5%. Pasithea Therapeutics is the larger company by market cap ($15.6 million vs $14.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACTU | KTTA |
|---|---|---|
| Share price | $0.6102 | $0.4675 |
| Market cap | $14.65M | $15.62M |
| 1-day change | -10.13% | +6.03% |
| YTD return | -90.03% | -63.76% |
| 1-year return | -92.46% | -40.82% |
| 5-year return | — | -99.22% |
| EPS (TTM) | $-0.87 | $-1.59 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.49 | $2.06 |
| 52-week low | $0.604 | $0.281 |
| Distance from 52-week high | -92.81% | -77.31% |
| Analyst consensus | none | none |
| Avg. price target upside | +1814.13% | +541.71% |
| Average volume | 386.51K | 225.69K |
| Shares outstanding | 24.01M | 33.41M |
| Employees | 12 | 5 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KTTA has outperformed ACTU by 51.6 percentage points over the past year.
About Actuate Therapeutics
ACTU stock →Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
About Pasithea Therapeutics
KTTA stock →Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumor; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
ACTU vs KTTA FAQ
Which is bigger, Actuate Therapeutics or Pasithea Therapeutics?
Pasithea Therapeutics (KTTA) is larger, with a market capitalization of $15.62M compared with $14.65M for Actuate Therapeutics (ACTU).
Which stock has performed better over the past year, ACTU or KTTA?
KTTA returned -40.82% over the past 12 months, compared with -92.46% for ACTU (price return, excluding dividends). Past performance does not predict future results.
Are Actuate Therapeutics and Pasithea Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.